Sign in

You're signed outSign in or to get full access.

CB

Cabaletta Bio, Inc. (CABA)·Q1 2024 Earnings Summary

Executive Summary

  • Q1 2024 advanced CABA-201 across multiple autoimmune indications, reported no CRS or ICANS in the first patients dosed in RESET-Myositis and RESET-SLE, and set specific near-term data catalysts (EULAR June 14) .
  • Operating expenses rose (R&D $22.0M; G&A $6.1M), widening net loss to $25.0M and EPS to -$0.51; cash and investments were $223.8M, with runway into 1H26 maintained .
  • Strategic innovations: evaluating CABA-201 without preconditioning via RESET-PV sub-study and presenting apheresis-free manufacturing feasibility (whole blood) at ASGCT, potentially improving access and scalability .
  • Stock-relevant catalysts in the near term include initial clinical data presentations (EULAR) and continued trial site activation/enrollment; management highlighted a growing site footprint and enrollment momentum heading into 2H24 .

What Went Well and What Went Wrong

What Went Well

  • No CRS or ICANS of any grade observed in the first patients dosed in RESET-Myositis and RESET-SLE during the 28-day DLT window, supporting safety consistency with academic CD19-CAR T experiences .
  • Management emphasized progress on patient/physician experience: “evaluating CABA-201 without preconditioning” via RESET-PV sub-study and potential elimination of apheresis through whole-blood manufacturing; quote: “we demonstrated the potential to eliminate the need for apheresis by using a blood draw…” .
  • Clear near-term clinical readouts: initial translational and clinical data to be presented at EULAR (June 14), plus 2H24 initial data in SSc and gMG, reinforcing a robust catalyst calendar .

What Went Wrong

  • Elevated spending widened losses: R&D rose to $22.0M (vs $12.4M YoY), G&A to $6.1M (vs $4.5M YoY), driving net loss to $25.0M and EPS to -$0.51 .
  • Cash declined quarter-over-quarter ($223.8M vs $241.2M), reflecting operating burn despite maintained multi-year runway into 1H26 .
  • Enrollment started modestly and is ramping; management acknowledged the logistical complexity of autoimmune CAR-T site activation across specialties and highlighted a growing network (18 sites open; 5 patients enrolled as of mid-June), which introduces operational execution risk and timeline variability .

Financial Results

Income and Expense Trends

Metric ($USD Millions except per-share)Q3 2023Q4 2023Q1 2024
Research & Development$13.8 $17.4 $22.0
General & Administrative$4.9 $5.7 $6.1
Total Operating Expenses$18.7 $23.1 $28.0
Interest Income$2.2 $2.3 $3.0
Net Loss$(16.4) $(20.9) $(25.0)
Net Loss per Share (basic & diluted)$(0.37) $(0.46) $(0.51)

Notes: Statements of operations presented as operating expenses and other income; no revenue line was presented in Q1 2024 press release .

Balance Sheet Snapshot

Metric ($USD Millions)Q3 2023 (Sep 30)Q4 2023 (Dec 31)Q1 2024 (Mar 31)
Cash, Cash Equivalents & Investments$164.4 $241.2 $223.8
Total Assets$173.3 $253.7 $240.5
Total Liabilities$12.4 $17.5 $18.7
Stockholders’ Equity$160.9 $236.2 $221.7

Segment Breakdown

  • Not applicable (clinical-stage; no reported product revenue; operations reported as expenses and other income) .

KPIs (Clinical Execution and Safety)

KPIQ3 2023Q4 2023Q1 2024
First patients targeted for initial data (lupus/myositis)Initial data expected 1H24 First patient dosed; initial data 1H24 No CRS/ICANS observed in first lupus/myositis patients; data to be presented at EULAR 6/14
Sites Open (RESET Program)——18 sites (as of June 14)
Patients Enrolled (Program)——5 enrolled (as of June 14)
Safety (CRS/ICANS in first patients)——None observed during 28-day DLT window

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Cash RunwayMulti-yearInto 1H26 (Dec 31, 2023 base) Into 1H26 (Mar 31, 2024 base) Maintained
Initial Clinical Data – Myositis & SLE1H24Initial data in 1H24 Initial data at EULAR on June 14 Maintained; timing specified
Initial Clinical Data – SSc & gMG2H24Initial data in 2H24 Initial data in 2H24 Maintained
RESET-PV Sub-study (No Preconditioning)2024Not previously statedInitiated sub-study to evaluate CABA-201 monotherapy without preconditioning in PV New program element
Apheresis-Free Manufacturing Evaluation2024Not previously statedWhole blood-based manufacturing feasibility presented; evaluating incorporation into program New process innovation

Earnings Call Themes & Trends

TopicPrevious Mentions (Q-2: Q3 2023)Previous Mentions (Q-1: Q4 2023)Current Period (Q1 2024)Trend
Safety (CRS/ICANS)Academic case series favorable; planning First patient dosed; no CRS/ICANS at 21 days No CRS/ICANS in first myositis and SLE patients (28-day DLT) Strengthening safety signals
Trial Enrollment & SitesProgram expansion; INDs cleared Active U.S. site recruitment 18 sites opened; 5 patients enrolled; ramping Accelerating footprint
Preconditioning StrategyCAART combo cohorts under evaluation Standard preconditioning regimen planned Initiating RESET-PV sub-study without preconditioning Broadening to no-preconditioning
Manufacturing ScalabilityPartnerships and CDMO strategy Preparing commercial-ready process; CDMO expansion Whole blood manufacturing feasibility; assessing apheresis-free incorporation Process innovation
Regulatory DesignationsInitial Fast Track clearances (SSc/gMG INDs) Fast Track in dermatomyositis and SSc; Orphan in myositis/SSc; Rare Pediatric Disease in JDM Continued utilization of designations; juvenile myositis cohort added Expanding regulatory leverage
Cash RunwayInto 4Q25 Into 1H26 Into 1H26 Maintained, extended in Q4

Management Commentary

  • CEO framing on safety and trial innovation: “With no CRS or ICANS… we look forward to presenting initial translational and clinical data… evaluating CABA-201 without preconditioning… eliminate the need for apheresis by using a blood draw…” .
  • Special Call tone on replication of academic profile: “we are encouraged by… no CRS, ICANS or infections… data… supportive of the dose we’re developing” .
  • Strategy on enrollment/site activation: “18 clinical sites open… seeing enrollment ramp up… provides the foundation for accelerated enrollment” .
  • Regulatory pathway intent: separate disease-specific INDs and cohorts to enable rigorous, homogeneous datasets and potential direct expansion to registrational designs post initial cohorts .

Q&A Highlights

  • Enrollment logistics and cadence: ~2–3 months from enrollment to dosing typical; complex cross-specialty handoffs; plan to expand sites across diseases for leadership in autoimmune CAR-T enrollment .
  • B-cell phenotyping: observed elimination and repopulation skewed toward transitional/naive B cells, consistent with immune reset; will incorporate markers used by academic groups and deeper BCR sequencing .
  • CAR-T expansion kinetics: peak around day 15 in reported cases (frozen product dynamics), with early interferon-gamma suggesting tissue engagement before peripheral peak; efficacy tracks academic data despite kinetic differences .
  • Regulatory discussions: plan to engage FDA post-completion of cohorts with robust efficacy and safety datasets; design choices aim to streamline pivot into registrational frameworks without entirely new trials .

Estimates Context

  • Wall Street consensus for Q1 2024 EPS and revenue via S&P Global was unavailable at time of request; comparison vs estimates cannot be provided.
  • Actual Q1 EPS was -$0.51 and net loss was $25.0M; operating results comprised expenses and interest income without a revenue line presented in the press release .
  • Expect sell-side models to adjust for higher near-term R&D and G&A spend given program expansion and multiple cohorts proceeding in parallel .

Key Takeaways for Investors

  • Near-term catalyst density high: initial safety/biologic signals presented at EULAR; additional follow-up for myositis/SLE and first data from SSc/gMG expected in 2H24 – potential narrative inflection if early efficacy durability tracks academic case series .
  • Safety profile to date (no CRS/ICANS) is stock-supportive; broader, consistent signals across cohorts will be key for valuation re-rating and eventual registrational dialogue .
  • Execution watchlist: enrollment velocity and site onboarding across rheumatology/neurology/nephrology; management cites ramp and industry-leading site count, but timelines remain operationally sensitive .
  • Process innovation could be a long-term differentiator: apheresis-free manufacturing and no-preconditioning PV sub-study may reduce patient burden and expand addressability, improving long-run commercial feasibility .
  • Cash runway into 1H26 supports multi-indication execution without near-term financing; monitor burn trajectory as trials scale and additional cohorts activate .
  • Regulatory pathway design (separate INDs/cohorts) may shorten time-to-pivotal by enabling cohort expansion/add-on comparators rather than launching new trials; watch for FDA interactions post initial cohort completions .
  • Absence of revenue and widened losses are expected for clinical-stage biotech; stock likely trades on clinical/scientific milestones, safety durability, and operational execution into 2H24 .